Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | butyrylcholinesterase | Starlite/ChEMBL | References |
Rattus norvegicus | Anandamide amidohydrolase | Starlite/ChEMBL | References |
Homo sapiens | fatty acid amide hydrolase | Starlite/ChEMBL | References |
Homo sapiens | acetylcholinesterase (Yt blood group) | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus granulosus | fatty acid amide hydrolase 1 | Anandamide amidohydrolase | 579 aa | 470 aa | 28.7 % |
Brugia malayi | Carboxylesterase family protein | butyrylcholinesterase | 602 aa | 546 aa | 30.2 % |
Brugia malayi | Carboxylesterase family protein | acetylcholinesterase (Yt blood group) | 614 aa | 510 aa | 26.5 % |
Echinococcus multilocularis | fatty acid amide hydrolase 1 | Anandamide amidohydrolase | 579 aa | 470 aa | 28.3 % |
Schistosoma japonicum | Fatty-acid amide hydrolase 1, putative | Anandamide amidohydrolase | 579 aa | 499 aa | 24.6 % |
Onchocerca volvulus | Anandamide amidohydrolase | 579 aa | 539 aa | 34.7 % | |
Leishmania major | hypothetical protein, conserved | fatty acid amide hydrolase | 579 aa | 471 aa | 26.5 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | hypothetical protein | 0.0967 | 1 | 0.5 |
Echinococcus multilocularis | fatty acid amide hydrolase 1 | 0.0246 | 0.2003 | 1 |
Mycobacterium leprae | NADH-DEPENDENT ENOYL-[ACYL-CARRIER-PROTEIN] REDUCTASE INHA (NADH-DEPENDENT ENOYL-ACP REDUCTASE) | 0.0967 | 1 | 1 |
Onchocerca volvulus | 0.0066 | 0 | 0.5 | |
Echinococcus granulosus | fatty acid amide hydrolase 1 | 0.0246 | 0.2003 | 1 |
Plasmodium vivax | enoyl-acyl carrier protein reductase | 0.0967 | 1 | 1 |
Echinococcus multilocularis | acetylcholinesterase | 0.0164 | 0.1089 | 0.5435 |
Mycobacterium ulcerans | enoyl-(acyl carrier protein) reductase | 0.0967 | 1 | 1 |
Brugia malayi | Carboxylesterase family protein | 0.0164 | 0.1089 | 0.5435 |
Onchocerca volvulus | 0.0066 | 0 | 0.5 | |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.0164 | 0.1089 | 0.5435 |
Brugia malayi | amidase | 0.0246 | 0.2003 | 1 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.0164 | 0.1089 | 0.5435 |
Echinococcus granulosus | acetylcholinesterase | 0.0164 | 0.1089 | 0.5435 |
Trypanosoma brucei | oxidoreductase-like protein | 0.0066 | 0 | 0.5 |
Echinococcus granulosus | acetylcholinesterase | 0.0164 | 0.1089 | 0.5435 |
Echinococcus multilocularis | fatty acid amide hydrolase 1 | 0.0246 | 0.2003 | 1 |
Mycobacterium tuberculosis | NADH-dependent enoyl-[acyl-carrier-protein] reductase InhA (NADH-dependent enoyl-ACP reductase) | 0.0967 | 1 | 1 |
Leishmania major | 3-oxoacyl-ACP reductase, putative | 0.0066 | 0 | 0.5 |
Loa Loa (eye worm) | carboxylesterase | 0.0164 | 0.1089 | 0.5435 |
Brugia malayi | Carboxylesterase family protein | 0.0164 | 0.1089 | 0.5435 |
Echinococcus granulosus | carboxylesterase 5A | 0.0164 | 0.1089 | 0.5435 |
Echinococcus multilocularis | carboxylesterase 5A | 0.0164 | 0.1089 | 0.5435 |
Echinococcus multilocularis | acetylcholinesterase | 0.0164 | 0.1089 | 0.5435 |
Leishmania major | dehydrogenase/oxidoreductase-like protein | 0.0066 | 0 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | enoyl-ACP reductase | 0.0967 | 1 | 1 |
Trypanosoma brucei | pteridine reductase 1 | 0.0066 | 0 | 0.5 |
Entamoeba histolytica | 3-oxoacyl-(acyl-carrier protein) reductase, putative | 0.0066 | 0 | 0.5 |
Schistosoma mansoni | fatty-acid amide hydrolase | 0.0246 | 0.2003 | 1 |
Leishmania major | pteridine reductase 1 | 0.0066 | 0 | 0.5 |
Trypanosoma cruzi | beta-ketoacyl-ACP reductase | 0.0066 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0164 | 0.1089 | 0.5435 |
Leishmania major | oxidoreductase-like protein | 0.0066 | 0 | 0.5 |
Echinococcus granulosus | fatty acid amide hydrolase 1 | 0.0246 | 0.2003 | 1 |
Toxoplasma gondii | enoyl-acyl carrier reductase ENR | 0.0967 | 1 | 1 |
Trypanosoma cruzi | oxidoreductase-like protein, putative | 0.0066 | 0 | 0.5 |
Plasmodium falciparum | enoyl-acyl carrier reductase | 0.0967 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0246 | 0.2003 | 1 |
Leishmania major | dehydrogenase/oxidoreductase-like protein | 0.0066 | 0 | 0.5 |
Schistosoma mansoni | amidase | 0.0246 | 0.2003 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0164 | 0.1089 | 0.5435 |
Trypanosoma cruzi | beta-ketoacyl-ACP reductase | 0.0066 | 0 | 0.5 |
Trypanosoma brucei | beta-ketoacyl-ACP reductase | 0.0066 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 11.2 nM | Inhibition of human serum BuChE using butyrylthiocholine iodide as substrate preincubated for 15 mins before substrate addition by Ellman's method | ChEMBL. | 24900454 |
IC50 (binding) | = 119 nM | Inhibition of human recombinant AChE using acetylthiocholine iodide as substrate preincubated for 120 mins before substrate addition by Ellman's method | ChEMBL. | 24900454 |
IC50 (binding) | = 1820 nM | Inhibition of FAAH in rat brain membranes assessed as hydrolysis of [14C]-anandamide preincubated for 20 mins before [14C]-anandamide addition measured after 30 mins | ChEMBL. | 24900454 |
IC50 (binding) | = 5590 nM | Inhibition of FAAH in rat brain membranes assessed as hydrolysis of [14C]-anandamide after 30 mins | ChEMBL. | 24900454 |
IC50 (binding) | = 14840 nM | Inhibition of human recombinant FAAH in assessed as hydrolysis of [14C]-anandamide preincubated for 20 mins before [14C]-anandamide addition measured after 30 mins | ChEMBL. | 24900454 |
Inhibition (binding) | Inhibition of human serum BuChE using butyrylthiocholine iodide as substrate by Ellman's method | ChEMBL. | 24900454 | |
Inhibition (binding) | Inhibition of human recombinant AChE using acetylthiocholine iodide as substrate by Ellman's method | ChEMBL. | 24900454 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.